CAR T Cell Therapy for UPSC: What It Is, Why NexCAR19 Matters, How It Gets Asked
CAR T cell therapy explained for UPSC: the mechanism in plain language, India's indigenous NexCAR19 story, the regulatory framework, the limits nobody mentions, and the prelims and mains angles worth remembering.
CAR T cell therapy explained for UPSC: the mechanism in plain language, India's indigenous NexCAR19 story, the regulatory framework, the limits nobody mentions, and the prelims and mains angles worth remembering.
What CAR T cell therapy actually is
CAR T cell therapy is a form of cancer immunotherapy in which a patient's own T cells are taken out, genetically engineered in a lab to carry a Chimeric Antigen Receptor (CAR) that recognises a specific protein on cancer cells, multiplied, and infused back into the same patient. Because the modified cells keep dividing inside the body, it is often called a living drug: one infusion, not a course of doses. For UPSC, it sits at the intersection of biotechnology, gene therapy and health financing, and the reason it entered the syllabus conversation is NexCAR19, approved by India's drug regulator in October 2023.
The engineered receptor is chimeric because it is stitched together from parts of different molecules. One end sits outside the cell and grabs the target antigen, usually CD19 on B cells. The other end sits inside and fires the T cell's killing machinery. Normal T cells often fail to spot cancer cells at all. The CAR removes that blind spot.
One clarification that is worth carrying into the exam hall. This is somatic gene therapy done ex vivo, outside the body, on one person's immune cells. Nothing is changed in the egg or sperm, so nothing is passed to the next generation.
The five steps, in order
If a question asks you to describe the process, write it as a sequence. Examiners reward order.
- Leukapheresis: blood is drawn and T cells are separated out.
- Genetic modification: a viral vector (usually lentiviral) inserts the gene for the CAR into those T cells.
- Expansion: the modified cells are multiplied in the lab over roughly two to three weeks.
- Lymphodepletion: the patient gets low-dose chemotherapy to make room for the new cells.
- Infusion and persistence: the CAR T cells are put back, hunt CD19-positive cells, and keep multiplying in the body.
NexCAR19: why India's version is the story
The world's first CAR T product, Kymriah, was cleared by the US FDA in 2017. It cost around 475,000 dollars. At Indian exchange rates that is a therapy that exists in journals and nowhere else, which is exactly the problem NexCAR19 was built to solve.
NexCAR19, generic name actalycabtagene autoleucel, came out of a long collaboration between IIT Bombay and Tata Memorial Centre, commercialised through ImmunoACT, a company incubated at IIT Bombay. CDSCO approved it in October 2023 for relapsed or refractory B-cell lymphoma and B-cell acute lymphoblastic leukaemia in patients aged 15 and above. It was formally launched at IIT Bombay in April 2024. Price: roughly 30 to 40 lakh rupees, which is still enormous for an Indian family and still a fraction of the global tag.
That gap is the whole point. India built the vector, the manufacturing and the clinical trial capacity domestically instead of importing a finished product, and it became the first low- or middle-income country to license its own CAR T therapy. Use that line in a mains answer on indigenous innovation. It does more work than the word breakthrough ever will.
| Year | Milestone |
|---|---|
| 2017 | US FDA approves Kymriah (tisagenlecleucel), the first CAR T therapy anywhere |
| 2018 onwards | IIT Bombay and Tata Memorial Centre develop an indigenous CD19 CAR T construct |
| 2021 | First-in-human academic trial of the Indian product begins at Tata Memorial Hospital |
| Oct 2023 | CDSCO approves NexCAR19, India's first indigenous CAR T cell therapy |
| Apr 2024 | Formal launch at IIT Bombay |
The limits, which is where good answers separate themselves
CAR T therapy is not a general cancer cure, and writing as though it is will cost you marks. It works well in blood cancers of B-cell origin because CD19 is a clean, uniform target. Solid tumours are a different beast. Their antigens vary from cell to cell, the tumour microenvironment suppresses T cells, and the cells struggle to physically reach the tumour core. No solid tumour CAR T product has broad approval yet.
Then the toxicity. Cytokine release syndrome is the big one: the activated cells flood the body with cytokines, causing high fever, low blood pressure and organ stress. There is also neurotoxicity, known as ICANS, which can look like confusion or seizures. And because the therapy wipes out healthy B cells along with cancerous ones, patients face months of infection risk. Both need hospitals with intensive care, which means the therapy is realistically available in a handful of Indian centres.
Manufacturing is the third constraint. Each dose is made from one patient's own cells, so it cannot be mass produced or stockpiled. Research is moving towards allogeneic off-the-shelf CAR T cells from healthy donors, and towards engineering the cells inside the body rather than in a lab. Neither is standard care yet.
Regulation is worth one line in an answer. Gene therapy products in India are governed under the New Drugs and Clinical Trials Rules, 2019, with the DBT-ICMR National Guidelines for Gene Therapy Product Development and Clinical Trials, 2019, and approvals run through CDSCO.
How UPSC is likely to ask it
For prelims, expect statement-based traps rather than definitions. Is CAR T therapy heritable? No. Does it use the patient's own cells? Yes, in the approved autologous products. Does it edit the cancer cell's DNA? No, it modifies immune cells. Look at how the exam handled mitochondrial replacement therapy in 2021 and you will see the pattern: they test whether you understand the mechanism, not whether you memorised the name.
For mains, this belongs in GS Paper 3. Two framings carry most of the value. First, indigenous biotechnology: a public institute and a public hospital taking a therapy from bench to licence, at a tenth of the global price. Second, access: a 30 lakh rupee one-time therapy in a country where out-of-pocket spending dominates health expenditure, and where PMJAY does not cover it. That tension between capability and affordability is the essay-grade insight.
If you remember one sentence from this page, make it this. CAR T cell therapy proved India can manufacture a complex living drug; whether Indians can afford it is a separate question, and that is the question worth writing about.
FAQs
1. Is CAR T cell therapy the same as gene therapy?
It is a type of gene therapy, specifically somatic and ex vivo. A gene for the chimeric antigen receptor is inserted into the patient's T cells outside the body, so the change affects only that patient and is not inherited by their children.
2. Which cancers can NexCAR19 treat?
NexCAR19 is approved for relapsed or refractory B-cell lymphoma and B-cell acute lymphoblastic leukaemia in patients aged 15 years and above. It targets the CD19 protein, so it does not work on cancers that lack that marker, including solid tumours.
3. Why doesn't CAR T therapy work well on solid tumours like breast or lung cancer?
Solid tumours lack a single uniform surface antigen, their microenvironment actively suppresses T cells, and the engineered cells struggle to penetrate dense tumour tissue. Trials are ongoing, but no solid tumour CAR T product has broad regulatory approval yet.
4. What is cytokine release syndrome?
It is the most common serious side effect of CAR T therapy, caused by a sudden surge of cytokines when the engineered T cells activate en masse. Symptoms range from high fever and low blood pressure to organ dysfunction, and it usually needs intensive care management.
5. Who regulates CAR T and other gene therapies in India?
CDSCO grants approvals under the New Drugs and Clinical Trials Rules, 2019, guided by the DBT-ICMR National Guidelines for Gene Therapy Product Development and Clinical Trials, 2019. Institutional ethics committees and biosafety committees clear the trials at the research stage.
6. How much does CAR T therapy cost in India compared to abroad?
NexCAR19 is priced at roughly 30 to 40 lakh rupees, against 300,000 to 475,000 dollars for approved products in the United States and Europe. It is still not covered by PMJAY, so most of the cost falls on the patient.